KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 7028 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. PMID 37866811 · Ann Oncol · 2024-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Participant Safety in Multisite, Randomized, Double-Blind, Placebo-Controlled Clinical Trials in Hospice/Palliative Care: Data from the Contracted Studies of the Australian National Palliative Care Clinical Studies Collaborative. PMID 37824800 · J Palliat Med · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. PMID 37804344 · Ann Hematol · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study. PMID 37794628 · Diabetes Obes Metab · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. PMID 37777832 · Clin Pharmacol Ther · 2024-Jan Phase II randomized trial with drug intervention and original results, but primary endpoint is locoregional control at 18 months (not a standard time-to-event endpoint like OS/PFS/DFS/EFS/RFS/TTP). Abstract does not report Kaplan-Meier survival curves, hazard ratios, or other time-to-event analyses.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. PMID 37737952 · BioDrugs · 2024-Jan The study is a randomized Phase III trial with a drug intervention and a primary efficacy endpoint. However, it is not an oncology study (it investigates spondyloarthritis) and does not have a time-to-event primary or key secondary endpoint. Therefore, it fails the fundamental oncology and time-to-event criteria for the cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group. PMID 37735258 · Eur J Nucl Med Mol Imaging · 2024-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 1 Panel · risk visible
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial. PMID 37713021 · Paediatr Drugs · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. PMID 37625434 · Lancet Infect Dis · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis. PMID 37455237 · J Cyst Fibros · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up. PMID 37345861 · Int Forum Allergy Rhinol · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. PMID 37061109 · Clin Gastroenterol Hepatol · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Acceptability, feasibility and preliminary efficacy of low-moderate intensity Constraint Induced Aphasia Therapy and Multi-Modality Aphasia Therapy in chronic aphasia after stroke. PMID 37036031 · Top Stroke Rehabil · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. PMID 38381664 · N Engl J Med · 2024-Feb-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. PMID 37962077 · N Engl J Med · 2024-Feb-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Feasibility of online managing cancer and living meaningfully (CALM) in Chinese patients with metastatic breast cancer: a pilot randomized control trial. PMID 38418478 · Sci Rep · 2024-Feb-28 The study is a pilot randomized trial of a psychotherapy intervention (CALM) for psychological outcomes in metastatic breast cancer. It is not a drug intervention, and the primary outcomes (death anxiety, depression, distress, etc.) are not time-to-event efficacy endpoints (OS, PFS, DFS, etc.). Additionally, the study is described as a pilot RCT and recommends a future Phase III, so it is not a definitive Phase III/IIIb report.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial. PMID 38416865 · J Clin Psychiatry · 2024-Feb-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. PMID 38295339 · Neurology · 2024-Feb-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial. PMID 38185589 · Sci Bull (Beijing) · 2024-Feb-26 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial. PMID 38346442 · Lancet · 2024-Feb-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial. PMID 38395969 · Nat Commun · 2024-Feb-23 The record describes a Phase III randomized trial in oncology with a primary time-to-event efficacy endpoint (RFS), but the intervention is an autologous dendritic cell therapy, which is a cellular therapy/vaccine, not a drug. Per the adjudication criteria, drug intervention is required for eligibility, and we do not infer drug intervention from a therapy name.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study. PMID 36849205 · Br J Ophthalmol · 2024-Feb-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. PMID 38109213 · Clin Cancer Res · 2024-Feb-16 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 4 Panel · risk visible
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. PMID 38060199 · Clin Cancer Res · 2024-Feb-16 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Cefepime-Taniborbactam in Complicated Urinary Tract Infection. PMID 38354140 · N Engl J Med · 2024-Feb-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan. PMID 38267330 · Vaccine · 2024-Feb-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. PMID 37506264 · J Infect Dis · 2024-Feb-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). PMID 38350888 · BMC Cancer · 2024-Feb-13 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial. PMID 38348724 · Acta Derm Venereol · 2024-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. PMID 38346853 · J Immunother Cancer · 2024-Feb-12 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized confirmed 2 Figure · 3 Panel · risk visible
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. PMID 38310910 · Lancet · 2024-Feb-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. PMID 38096461 · J Clin Oncol · 2024-Feb-10 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Agreement among high-sensitivity cardiac troponin assays and non-invasive testing, clinical outcomes, and quality-of-care outcomes based on the 2020 European Society of Cardiology Guidelines. PMID 38001050 · Eur Heart J Acute Cardiovasc Care · 2024-Feb-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. PMID 38324483 · N Engl J Med · 2024-Feb-08 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials. PMID 37875349 · Sleep · 2024-Feb-08 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial. PMID 38240204 · J Am Heart Assoc · 2024-Feb-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. PMID 38335000 · JAMA Netw Open · 2024-Feb-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. PMID 38281499 · Lancet · 2024-Feb-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial. PMID 37699115 · Oncologist · 2024-Feb-02 This is a phase III randomized trial of melatonin in breast cancer patients, but its endpoints are symptom and quality-of-life measures (fatigue, etc.), not time-to-event outcomes like overall survival or progression-free survival. The deterministic review correctly identified a lack of time-to-event signal.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma. PMID 37589219 · Oncologist · 2024-Feb-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults. PMID 38294972 · N Engl J Med · 2024-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial. PMID 38227308 · JAMA Neurol · 2024-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. PMID 38117487 · JAMA Dermatol · 2024-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial. PMID 38095881 · JAMA Oncol · 2024-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. PMID 37992266 · J Clin Oncol · 2024-Feb-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. PMID 37963317 · J Clin Oncol · 2024-Feb-01 The study is a randomized Phase II/III oncology trial with a drug intervention, but the abstract does not report any time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR data. The primary results are pathologic/surgical outcomes and safety. Therefore, it does not meet the time-to-event endpoint criterion for inclusion.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907). PMID 37802225 · Int J Radiat Oncol Biol Phys · 2024-Feb-01 The trial is a randomized Phase III oncology study with a time-to-event primary endpoint (biochemical progression) and includes results. However, the core intervention under evaluation is the duration of androgen deprivation therapy (ADT), which is a standard-of-care hormonal manipulation, not a novel drug-containing regimen. The study compares two durations of an existing therapy, not a drug versus placebo or a new drug. Therefore, it does not meet the criterion of having a drug-containing intervention as defined for a drug development cohort.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age. PMID 38314063 · Influenza Other Respir Viruses · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: a single-masked, phase 3, superiority, randomised controlled trial. PMID 38310894 · Lancet Healthy Longev · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. PMID 38302221 · Lancet Haematol · 2024-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed